Skip to the main content.

Breast Cancer

Phase 3

Case Studies

Here you can edit the background of the section


High returns on recruitment campaigns for oncology indications are often hard-won. This truism was compounded for this Phase 3 study by the very particular recurrent breast cancer patient we sought. 

Our client felt the need to screen patients thoroughly prior to passing them on to sites, insisting on a depth of information more typically covered by an HCP. As a result, site receptivity to receiving any incoming referrals, to accepting the extent of pre-screening information collected and to expediting processing referrals varied significantly. 

With the sponsor wedded to an expansive prescreen, our job entailed ensuring that we didn’t overwhelm patients with overly detailed and hard-to-answer questions, while also collaborating closely with sites to process referrals.  


Advanced Breast Cancer Digital Ad


  • Our relatively rare patient audience had options besides clinical trials

  • Sites’ interest in and commitment to recruitment support proved inconsistent and varied

  • The client’s budget would only allow for a limited amount of referral management, leaving us unable to support all sites

  • Sites struggled to meet agreed-upon referral management best practices — with contact reach rates suffering at multiple sites accordingly  




Given the slow and uneven referral processing initially conducted by sites, it became clear that BBK needed to devise customized site-specific approaches and interventions.  

Instituting monthly “Referral Health Checks” per site proved essential to our ability to track both call center and site-level performance — enabling us to escalate unresponsive sites to the sponsor for assistance. 

With close collaboration, we were ultimately able to identify and prioritize those sites with the best potential for leveraging our services.







By prioritizing our support where we could have the greatest impact, key sites excelled; sites that declined any support saw precipitous drops in screening rates by comparison. 

BBK’s outreach initiatives generated five consented patients in 151 days, compared to the five generated prior to our involvement that required over 431 days. 

The ambient effect of our efforts reduced screening timelines for 17 supported sites by 280 days — increasing the screening rate by 180%. In contrast, non-supported sites’ screening rates decreased by 57% during this same time period. 

Without BBK’s assistance, achieving ten consented patients would have taken an additional two years. 


relapsed breast cancer case study
  • Sites_ICON 180% Increase in screening rates at BBK-supported sites

  • Participants_ICON 97% Referral target achieved (109 of 112)

  • Calendar_ICON 2+ Additional years that would have been required to reach enrollment goals without BBK

Download the PDF version of this case study today:

Subscribe to stay connected

Share this page:

Familial Amyloid Polyneuropathy — Neurology and Gene Therapy — Phase 3

case-studies-icon Case Studies

October 12, 2021

Pediatric Spinal Muscular Atrophy — Neurology and Rare Disease — Phase 2

case-studies-icon Case Studies

December 13, 2021

Major Depressive Disorder — Mental Health — Pivotal Phase 3 Study

case-studies-icon Case Studies

February 5, 2022

BBK Worldwide, LLC
117 Kendrick St., Suite 600
Needham, MA 02494 United States

        Terms & Conditions  Privacy Policy

        © 2023 BBK Worldwide. BBK Worldwide is a Publicis Health company.

        Facebook LinkedIn YouTube
        Facebook LinkedIn YouTube

        Terms & Conditions  Privacy Policy

        © 2023 BBK Worldwide. BBK Worldwide is a Publicis Health company.